| Literature DB >> 34258743 |
Tianguang Huang1, Lin Sun1, Dongwei Kang1, Vasanthanathan Poongavanam2, Xinyong Liu1, Peng Zhan1, Luis Menéndez-Arias3.
Abstract
Recent coronavirus outbreaks of SARS-CoV-1 (2002-2003), MERS-CoV (since 2012), and SARS-CoV-2 (since the end of 2019) are examples of how viruses can damage health care and generate havoc all over the world. Coronavirus can spread quickly from person to person causing high morbidity and mortality. Unfortunately, the antiviral armamentarium is insufficient to fight these infections. In this chapter, we provide a detailed summary of the current situation in the development of drugs directed against pandemic human coronaviruses. Apart from the recently licensed remdesivir, other antiviral agents discussed in this review include molecules targeting viral components (e.g., RNA polymerase inhibitors, entry inhibitors, or protease inhibitors), compounds interfering with virus-host interactions, and drugs identified in large screening assays, effective against coronavirus replication, but with an uncertain mechanism of action.Entities:
Keywords: Coronavirus; MERS-CoV; RNA polymerase; Remdesivir; SARS-CoV; Viral replication
Year: 2021 PMID: 34258743 DOI: 10.1007/978-981-16-0267-2_9
Source DB: PubMed Journal: Adv Exp Med Biol ISSN: 0065-2598 Impact factor: 2.622